CD44 and cancer: Hence, this study was designed to demonstrate that Er-loaded MoS2 modified with HA could be engineered as a photothermal-triggered drug delivery system to specially target the CD44-overexpressing cancer cells, deliver non-water-soluble drug Er into cells, produce NIR-mediated hyperthermia, stimulate drug release triggered by photothermic, resulting in a synergistic cancer therapeutic effect in vitro and in vivo.